Trust Co. of Toledo NA OH Has $83,000 Stock Holdings in Seelos Therapeutics, Inc. (NASDAQ:SEEL)

Trust Co. of Toledo NA OH boosted its holdings in shares of Seelos Therapeutics, Inc. (NASDAQ:SEEL) by 26.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 69,474 shares of the company’s stock after buying an additional 14,474 shares during the period. Trust Co. of Toledo NA OH owned approximately 0.06% of Seelos Therapeutics worth $83,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. First Republic Investment Management Inc. bought a new stake in shares of Seelos Therapeutics in the 1st quarter worth $34,000. Asset Management Corp IL ADV bought a new stake in shares of Seelos Therapeutics in the 1st quarter worth $28,000. Belpointe Asset Management LLC bought a new stake in shares of Seelos Therapeutics in the 4th quarter worth $34,000. Mariner LLC bought a new stake in shares of Seelos Therapeutics in the 4th quarter worth $36,000. Finally, Citigroup Inc. grew its stake in shares of Seelos Therapeutics by 113.3% in the 1st quarter. Citigroup Inc. now owns 53,533 shares of the company’s stock worth $45,000 after acquiring an additional 28,431 shares in the last quarter. Institutional investors and hedge funds own 17.97% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $2.00 target price on shares of Seelos Therapeutics in a research note on Tuesday, August 22nd.

Seelos Therapeutics Stock Performance

SEEL opened at $0.92 on Friday. The firm has a 50-day moving average of $1.26 and a 200 day moving average of $1.00. Seelos Therapeutics, Inc. has a fifty-two week low of $0.58 and a fifty-two week high of $1.66.

Seelos Therapeutics Company Profile

Seelos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD).